Article metrics

Download PDFPDF

753 An open-label, phase 1a/b study of AB248, a CD8+ selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to January 2024

AbstractFullPdf
Nov 2023228012
Dec 202366015
Jan 202479010
Total373037